Concepedia

Publication | Closed Access

Natalizumab versus fingolimod in patients with relapsing-remitting multiple sclerosis non-responding to first-line injectable therapies

DOI

68

Citations

28

References

2016

Year

Damiano Baroncini, Angelo Ghezzi, Pietro Annovazzi, B. Colombo, Vittorio Martinelli, G. Minonzio, Lucia Moiola, Mariaemma Rodegher, Mauro Zaffaroni
Multiple Sclerosis Journal

Abstract

Natalizumab is superior to fingolimod in RRMS patients non-responding to first-line agents.

References

YearCitations

Page 1